<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956692</url>
  </required_header>
  <id_info>
    <org_study_id>3475-A86</org_study_id>
    <secondary_id>MK-3475-A86</secondary_id>
    <secondary_id>2020-002729-27</secondary_id>
    <secondary_id>jRCT2021210032</secondary_id>
    <nct_id>NCT04956692</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)</brief_title>
  <official_title>A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC)&#xD;
      administration as the first-line therapy in the treatment of metastatic squamous and&#xD;
      nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of&#xD;
      pembrolizumab SC injection in combination with standard-of-care chemotherapy. The primary&#xD;
      hypothesis of the study is Pembrolizumab SC is noninferior to pembrolizumab intravenous (IV)&#xD;
      for Cycle 1 Area Under Curve (AUC) and Cycle 6 minimal concentration (Ctrough) at steady&#xD;
      state.&#xD;
&#xD;
      Participants who discontinue study treatment after receiving the first course of 35&#xD;
      administrations of pembrolizumab (approximately up to 2 years) for reasons other than disease&#xD;
      progression or intolerability, may be eligible for a second course of pembrolizumab for up to&#xD;
      approximately 1 additional year if they have experienced radiographic disease progression per&#xD;
      RECIST 1.1 as assessed by BICR after stopping first course treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">October 14, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab at Cycle 1</measure>
    <time_frame>Pharmacokinetic (PK) collection at designated timepoints in Cycle 1 (Up to approximately 3 weeks; cycle length = 3 weeks)</time_frame>
    <description>AUC0-3wks at Cycle 1 is defined as the area under curve exposure parameter over a 3-week dosing interval in Cycle 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal Concentration (Ctrough) of Pembrolizumab at the End of Cycle 6</measure>
    <time_frame>PK collection at end of Cycle 6 (approximately at end of Week 18; cycle length = 3 weeks)</time_frame>
    <description>Ctrough of Cycle 6 is defined as the observed trough concentration measured at the end of the dosing interval in Cycle 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response (OR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>The OR rate is defined as the percentage of participants who achieve a confirmed complete response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of Pembrolizumab at the End of Cycle 1</measure>
    <time_frame>PK collection at end of Cycle 1 (approximately at end of Week 3; cycle length = 3 weeks)</time_frame>
    <description>Ctrough of Cycle 1 is defined as the observed trough concentration at the end of the dosing interval in Cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Pembrolizumab at Cycle 1</measure>
    <time_frame>PK collection at designated timepoints in Cycle 1 (Up to approximately 3 weeks; cycle length = 3 weeks)</time_frame>
    <description>Cmax at Cycle 1 is defined as the observed peak concentration over the dosing interval in Cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-3wks of Pembrolizumab at Cycle 6</measure>
    <time_frame>PK collection at designated timepoints in Cycle 6 (Up to approximately 3 weeks; cycle length = 3 weeks)</time_frame>
    <description>AUC0-3wks at Cycle 6 is defined as the area under curve exposure parameter over a 3-week dosing interval in Cycle 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Pembrolizumab at Cycle 6</measure>
    <time_frame>PK collection at designated timepoints in Cycle 6 (Up to approximately 3 weeks; cycle length = 3 weeks)</time_frame>
    <description>Cmax at Cycle 6 is defined as the observed peak concentration over the dosing interval in Cycle 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 28 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to an AE</measure>
    <time_frame>Up to approximately 25 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>For participants who show confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibodies (ADAs) Incidence After Administration of Pembrolizumab</measure>
    <time_frame>Up to approximately 26 months</time_frame>
    <description>ADA incidence will be assessed by analyzing the development of ADAs following administration of pembrolizumab SC and pembrolizumab IV.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab subcutaneous (SC) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous NSCLC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive pembrolizumab intravenous (IV) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous NSCLC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab SC</intervention_name>
    <description>SC injection</description>
    <arm_group_label>Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab IV</intervention_name>
    <description>IV injection</description>
    <arm_group_label>Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV injection</description>
    <arm_group_label>Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy</arm_group_label>
    <other_name>Nov-Onxol</other_name>
    <other_name>Onxol</other_name>
    <other_name>Paclitaxel Novaplus</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy</arm_group_label>
    <other_name>Abraxane</other_name>
    <other_name>Nanoparticle albumin-bound paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin NovaPlus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy</arm_group_label>
    <other_name>Platinol-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy</arm_group_label>
    <other_name>LY231514</other_name>
    <other_name>Alimta</other_name>
    <other_name>Pemetrexed Disodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has pathologically (histologically or cytologically) confirmed diagnosis of squamous&#xD;
             or nonsquamous non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Has Stage IV (T any, N any, M1a, M1b, or M1c - American Joint Committee on Cancer 8th&#xD;
             Edition) squamous or nonsquamous NSCLC&#xD;
&#xD;
          -  Has confirmation that epidermal growth factor receptor (EGFR), Anaplastic lymphoma&#xD;
             kinase (ALK), or ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS1)-directed&#xD;
             therapy is not indicated in nonsquamous NSCLC as well as mixed nonsquamous/squamous&#xD;
             NSCLC. Participants with purely squamous NSCLC do not require testing&#xD;
&#xD;
          -  Has not received prior systemic treatment for their metastatic NSCLC. Participants who&#xD;
             received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant&#xD;
             therapy was completed at least 12 months prior to the development of metastatic&#xD;
             disease&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0 or 1&#xD;
&#xD;
          -  Male participants are eligible to participate if they agree to use contraception as&#xD;
             per protocol unless confirmed to be azoospermic&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, and at least one of the following conditions applies: is not a woman of&#xD;
             childbearing potential (WOCBP) or is a WOCBP who agrees of using a contraceptive&#xD;
             method per protocol&#xD;
&#xD;
          -  Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1&#xD;
             (RECIST 1.1) as assessed by the local site investigator/radiology&#xD;
&#xD;
          -  Submit an archival tumor tissue sample or newly obtained core or incisional biopsy of&#xD;
             a tumor lesion not previously irradiated for PD-L1 status determination prior to&#xD;
             randomization&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 3 years&#xD;
&#xD;
          -  Has known central nervous system (ie, brain and/or spinal cord) metastases and/or&#xD;
             carcinomatous meningitis. Participants with treated brain metastases may participate&#xD;
             only if they satisfy all of the following: a) Have no evidence of new or enlarging&#xD;
             brain metastases confirmed by post-treatment repeat brain imaging performed at least 4&#xD;
             weeks after pretreatment brain imaging, and b) Are neurologically stable without the&#xD;
             need for steroids for at least 14 days before first dose of trial treatment as per&#xD;
             local site assessment&#xD;
&#xD;
          -  Has severe hypersensitivity to study intervention and/or any of its excipients&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
&#xD;
          -  Has a history of (noninfectious) pneumonitis/interstitial lung disease that required&#xD;
             steroids or has current pneumonitis/interstitial lung disease&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) infection and/or Hepatitis B&#xD;
             infection or known active Hepatitis C infection&#xD;
&#xD;
          -  Has a known psychiatric or substance abuse disorder that would interfere with the&#xD;
             participant's ability to cooperate with the requirements of the study&#xD;
&#xD;
          -  Has symptomatic ascites or pleural effusion. A participant who is clinically stable&#xD;
             after treatment for these conditions is eligible&#xD;
&#xD;
          -  Before the first dose of study intervention: a) Has received prior systemic cytotoxic&#xD;
             chemotherapy for metastatic NSCLC b) Has received antineoplastic biological therapy&#xD;
             for metastatic NSCLC c) Has had major surgery (&lt;3 weeks prior to first dose) d) Has&#xD;
             received prior therapy with an anti-programmed cell death 1 (anti-PD-1),&#xD;
             anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand&#xD;
             2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory&#xD;
             T-cell receptor&#xD;
&#xD;
          -  Received radiation therapy to the lung that is &gt;30 Gray within 6 months of the first&#xD;
             dose of study intervention&#xD;
&#xD;
          -  Is expected to require any other form of antineoplastic therapy while on study&#xD;
&#xD;
          -  For participants with nonsquamous histology: Is unable to interrupt aspirin or other&#xD;
             Non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g/day,&#xD;
             for a 5-day period&#xD;
&#xD;
          -  For participants with nonsquamous histology: Is unable or unwilling to take folic acid&#xD;
             or vitamin B12 supplementation&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks of start of study intervention.&#xD;
             Participants must have recovered from all radiation-related toxicities, not require&#xD;
             corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted&#xD;
             for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease&#xD;
&#xD;
          -  Has received a live or live attenuated vaccine within 30 days prior to the first dose&#xD;
             of study intervention&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to the first dose of&#xD;
             study intervention&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             or any other form of immunosuppressive therapy within 7 days prior the first dose of&#xD;
             study intervention&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Holy Cross Hospital ( Site 0017)</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>954-267-7742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center ( Site 0058)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>406-238-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Tennessee Medical Center ( Site 0050)</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>229-234-1356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants, PA ( Site 0052)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-600-0900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology &amp; Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 0100)</name>
      <address>
        <city>Blacksburg</city>
        <state>Virginia</state>
        <zip>24060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>540-381-5291</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Regional du Cancer de Montpellier - ICM ( Site 1003)</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33467613042</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Pau ( Site 1016)</name>
      <address>
        <city>Pau</city>
        <state>Pyrenees-Atlantiques</state>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33559924848</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0602)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50222783107</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Privada Dr. Rixci Ramirez ( Site 0601)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>22789307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>INTERVASC ( Site 0605)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50259042511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grupo Angeles SA ( Site 0604)</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>23857572</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Regional de Sub Especialidades Médicas SA ( Site 0600)</name>
      <address>
        <city>Quetzaltenango</city>
        <zip>09001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50259450559</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1106)</name>
      <address>
        <city>Kecskemét</city>
        <state>Bacs-Kiskun</state>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3676516719</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1103)</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209323256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujita Health University Hospital ( Site 3007)</name>
      <address>
        <city>Toyoake</city>
        <state>Aichi</state>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-562-93-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital ( Site 3005)</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-89-964-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital ( Site 3006)</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-942-35-3311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center ( Site 3014)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-11-811-9111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Center ( Site 3003)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-701-9581</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center ( Site 3000)</name>
      <address>
        <city>Natori</city>
        <state>Miyagi</state>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-22-384-3151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital ( Site 3015)</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-22-222-6181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital ( Site 3016)</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-804-0101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka Medical and Pharmaceutical University Hospital ( Site 3017)</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-683-1221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center ( Site 3001)</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-92-852-0700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center ( Site 3002)</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-92-541-3231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital ( Site 3012)</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-86-223-7151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital ( Site 3019)</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-88-631-3111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital ( Site 3011)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3813-3111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 1201)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48501446778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225463066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Przychodnia Lekarska KOMED ( Site 1202)</name>
      <address>
        <city>Konin</city>
        <state>Wielkopolskie</state>
        <zip>62-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48632428009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1200)</name>
      <address>
        <city>Koszalin</city>
        <state>Zachodniopomorskie</state>
        <zip>75-581</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48943488400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPBU Clinic of Advanced medical technologies n.a. N. I. Pirogov ( Site 1406)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79111005005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1407)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219437168</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg Scientific-Practical Center of Specialized Kinds of Medical Care (o) ( Site 1424)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+7 (812) 573-91-31</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary-Chemotherapy #1 ( Site 1425)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+7 (843) 202-3-202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPb SBHI City Clinical Oncological Dispensary ( Site 1409)</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219437168</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>H.U. Vall de Hebron ( Site 1600)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932746085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramon Jimenez ( Site 1602)</name>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34959016737</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti ( Site 1603)</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34982296459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 1601)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34917277516</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital ( Site 2104)</name>
      <address>
        <city>Changhua</city>
        <zip>50006</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886-4-7238595 ext7791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital Hsin-Chu Branch ( Site 2103)</name>
      <address>
        <city>Hsinchu</city>
        <zip>300</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86635326151ext.4529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 2107)</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88673121101 ext.5651</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 2105)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535 ext.4289</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital ( Site 2106)</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886228757496</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation-Linkou Branch ( Site 2102)</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88633281200x2285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gulhane Egitim ve Arastirma Hastanesi ( Site 1704)</name>
      <address>
        <city>Ankara</city>
        <zip>06010</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905366401020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara Sehir Hastanesi ( Site 1702)</name>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905555306271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1701)</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905063509061</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inonu Universitesi Turgut Ozal Tip Merkezi ( Site 1707)</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+90 422 341 06 60</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center Mriya Med-Service ( Site 1805)</name>
      <address>
        <city>Kryvyi Rih</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>50000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380973567855</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal non profit enterprise Regional Clinical Oncology Center ( Site 1806)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503802915</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ukrainian Center of Tomotherapy ( Site 1807)</name>
      <address>
        <city>Kropyvnytskyi</city>
        <state>Kirovohradska Oblast</state>
        <zip>25011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380979428527</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center Asklepion LLC ( Site 1804)</name>
      <address>
        <city>Khodosivka</city>
        <state>Kyivska Oblast</state>
        <zip>08173</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503481865</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncology Centre ( Site 1809)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503818536</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death 1 (PD1, PD-1)</keyword>
  <keyword>Programmed Cell Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <keyword>Programmed Cell Death-Ligand 2 (PDL2, PD-L2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

